AbbVie ends agreement with Caribou, pulling plug on yet another oncology deal
27 Sep 2023
Cell TherapyImmunotherapyLicense out/inGene TherapyAcquisition
AbbVie decided to end an agreement with Caribou Biosciences focused on the development of next-generation, off-the-shelf CAR-T cell therapies. Caribou disclosed the move in a US securities filing, noting that AbbVie’s decision was based on its “strategic focus” and not related to the performance or results stemming from the collaboration.
Under the agreement – signed in 2021 – AbbVie made an upfront payment of $40 million, along with an equity investment in Caribou, to gain access to the latter’s CRISPR genome editing platform. The deal, which also included potential milestones of up to $300 million, aimed to overcome the rejection of allogeneic CAR-T cells by engineering the therapies to withstand host immune attack.
Caribou noted that it has been conducting preclinical work for two AbbVie programmes, each comprising one or more collaboration allogeneic CAR-T products directed toward the single cancer target or target combination. However, AbbVie has decided not to advance the two programmes, with the deal coming to an end on October 25.
AbbVie has recently exited a number of oncology partnerships, including an agreement with I-Mab to develop certain CD47 antibody compounds, including the programme’s lead drug lemzoparlimab, as well as a deal with Harpoon Therapeutics for the BCMA-targeting tri-specific T-cell-activating construct HPN217. In July, AbbVie terminated a collaboration with Jacobio Pharmaceuticals centred on the development and commercialisation of SHP2 inhibitorsSHP2 inhibitors.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.